Stock Movers US Bank Stocks Rout Deepens; Pharma Falls on Trump Ozempic Comments
Oct 17, 2025
Regional banks Zions Bancorp and Western Alliance are facing scrutiny after revealing loan fraud, sparking fears about the credit market's stability. In contrast, Truist Financial and Fifth Third Bank see slight gains post-earnings. On the pharmaceutical front, shares of Eli Lilly and Novo Nordisk tumble following President Trump's statements, suggesting the price of the diabetes drug Ozempic might drop significantly. This has raised concerns about the impact on the broader pharma market.
AI Snips
Chapters
Transcript
Episode notes
Regional Banks Back In Focus
- Regional banks are again in the spotlight after write-downs tied to alleged collateral fraud on loans to distressed-property funds.
- Some regional names like Truist and Fifth Third still showed pockets of strength after earnings and disclosures.
Pharma Stocks Drop On Price Talk
- Eli Lilly and Novo Nordisk shares fell hard after White House comments about steep price cuts for weight-loss drugs.
- The administration's posture signals potential margin pressure as talks about drug pricing advance.
Bank Stress Ripples Globally
- Weakness in regional banks rippled to global financial names with large European banks falling sharply.
- Big U.S. banks also slid despite strong earnings, showing market sensitivity to banking-sector stress.